DRUGS ACTING AT D-1 AND D-2 DOPAMINE-RECEPTORS INDUCE IDENTICAL PURPOSELESS CHEWING IN RATS WHICH CAN BE DIFFERENTIATED BY CHOLINERGIC MANIPULATION

被引:47
作者
COLLINS, P
BROEKKAMP, CLE
JENNER, P
MARSDEN, CD
机构
[1] KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,PARKINSONS DIS SOC,EXPTL RES LABS,MANRESA RD,LONDON SW3 6LX,ENGLAND
[2] ORGANON INT BV,DEPT CNS PHARMACOL,OSS,NETHERLANDS
关键词
PURPOSELESS CHEWING; D-1; RECEPTORS; D-2; CHOLINERGIC MANIPULATION; ACUTE DYSTONIA;
D O I
10.1007/BF02244250
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Purposeless chewing in rats was dose dependently increased by acute administration of the dopamine D-1 receptor agonist SKF 38393 (5-20 mg/kg), the D-2 receptor antagonist sulpiride (10-100 mg/kg) and the D-2 receptor agonist quinpirole (0.05-0.25 mg/kg). Only high doses of the D-1 receptor antagonist SCH 23390 (1 and 5 mg/kg) induced purposeless chewing. SCH 23390 (0.05 mg/kg) blocked SKF 38393 (20 mg/kg)-induced purposeless chewing, but had no effect on the purposeless chewing induced by sulpiride (100 mg/kg) or quinpirole (0.1 mg/kg). A dose of SKF 38393 (5 mg/kg) which did not itself induce chewing, potentiated the increase in purposeless chewing observed after administration of sulpiride (100 mg/kg). Administration of SKF 38393 (20 mg/kg) and quinpirole (0.1 mg/kg) did not induce purposeless chewing but stereotyped licking was observed. Administration of sulpiride (100 mg/kg) with quinpirole (0.1 mg/kg) produced an incidence of purposeless chewing not different from that observed when either compound was administered alone. Acute administration of the cholinergic agonist pilocarpine (0.5-4.0 mg/kg) or the cholinesterase inhibitor physostigmine (0.05-0.2 mg/kg) increased the frequency of purposeless chewing in rats. Co-administration of pilocarpine (0.5 mg/kg) with sulpiride (100 mg/kg) increased the frequency of purposeless chewing above that seen when either compound was administered alone. Co-administration of pilocarpine (0.5 mg/kg) with SKF 38393 (20 mg/kg) increased the frequency of purposeless chewing in an additive manner. Co-administration of physostigmine (0.1 mg/kg) with sulpiride (100 mg/kg) but not SKF 38393 (20 mg/kg), increased the frequency of purposeless chewing above that observed when either compound was administered alone. Quinpirole (0.1 mg/kg)-induced purposeless chewing was not affected by co-administration with either pilocarpine (0.5 mg/kg) or physostigmine (0.1 mg/kg). The anticholinergic agent scopolamine (0.1 mg/kg) blocked the purposeless chewing induced by either SKF 38393 (20 mg/kg) or sulpiride (100 mg/kg), but had no effect on the purposeless chewing induced by quinpirole (0.1 mg/kg). Contrary to previous reports, acute manipulation of D-1 or D-2 receptor function can both enhance purposeless chewing behaviour in rats. These apparently identical behaviours can be differentiated by the response to cholinergic manipulation.
引用
收藏
页码:503 / 512
页数:10
相关论文
共 30 条
[2]  
ARNT J, 1986, ACTA PHARMACOL TOX, V59, P319
[3]   DOPAMINE D-1 RECEPTOR AGONISTS COMBINED WITH THE SELECTIVE D-2 AGONIST QUINPIROLE FACILITATE THE EXPRESSION OF ORAL STEREOTYPED BEHAVIOR IN RATS [J].
ARNT, J ;
HYTTEL, J ;
PERREGAARD, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 133 (02) :137-145
[4]   INHIBITION OF SKF38393-INDUCED AND PERGOLIDE-INDUCED CIRCLING IN RATS WITH UNILATERAL 6-OHDA LESION IS CORRELATED TO DOPAMINE D-1 AND D-2 RECEPTOR AFFINITIES INVITRO [J].
ARNT, J ;
HYTTEL, J .
JOURNAL OF NEURAL TRANSMISSION, 1986, 67 (3-4) :225-240
[5]   THE D-1 DOPAMINE RECEPTOR ANTAGONIST SCH 23390 ALSO INTERACTS POTENTLY WITH BRAIN-SEROTONIN (5-HT2) RECEPTORS [J].
BISCHOFF, S ;
HEINRICH, M ;
SONNTAG, JM ;
KRAUSS, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 129 (03) :367-370
[6]   OBLIGATORY D-1 D-2 RECEPTOR INTERACTION IN THE GENERATION OF DOPAMINE AGONIST RELATED BEHAVIORS [J].
BRAUN, AR ;
CHASE, TN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 131 (2-3) :301-306
[7]   CEREBRAL DOPAMINE FUNCTION IN RATS FOLLOWING WITHDRAWAL FROM ONE YEAR OF CONTINUOUS NEUROLEPTIC ADMINISTRATION [J].
CLOW, A ;
THEODOROU, A ;
JENNER, P ;
MARSDEN, CD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1980, 63 (2-3) :145-157
[8]  
CONSOLO S, 1987, J PHARMACOL EXP THER, V242, P300
[9]   OPPOSING EFFECTS OF D-1 AND D-2 RECEPTOR ANTAGONISTS ON ACETYLCHOLINE LEVELS IN THE RAT STRIATUM [J].
FAGE, D ;
SCATTON, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 129 (03) :359-362
[10]   FUNCTIONAL ANTAGONISM OF D-1 AND D-2 DOPAMINERGIC MECHANISMS AFFECTING STRIATAL ACETYLCHOLINE-RELEASE [J].
GORELL, JM ;
CZARNECKI, B ;
HUBBELL, S .
LIFE SCIENCES, 1986, 38 (24) :2247-2254